2 Drug Developers Latest To Tap Market With $275M On Offer

Law360, New York (March 17, 2015, 7:58 PM EDT) -- GlycoMimetics Inc. and Egalet Corp. filed for follow-on offerings Tuesday looking to raise a total of $275 million to fund further drug development becoming the latest of several drug developers that have turned to the public markets in recent weeks.

GlycoMimetics and Egalet filed shelf registration statements with the U.S. Securities and Exchange Commission to sell $150 million and $125 million in shares, respectively, as the companies are looking to fund further trials of their lead drug candidates.

Maryland-based GlycoMimetics, which went public in a $57.2 million initial public offering in January 2014, develops glycomimetic drugs, which use molecules that mimic...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!